Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > We're still...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(331)
•••
Comment by regardlesson Feb 16, 2021 1:40pm
145 Views
Post# 32574917

RE:RE:RE:We're still...

RE:RE:RE:We're still...heres the other issue...
we cant sit back and have the old status quo of them keeping data "secret" because the partner doesnt want it to get it...

its been going on for years and if they want it that way the company ought to denand monetry compensation for hving our shre price beaten down because the market cant guage what we have caus eits a big dckin secret....

i know alot of us 9plus year holders are sick of it ....

but in all honesty i dont think she has these results or deals set inplace otherwise she has to disclose them no matter whn they drop...it can be a saturday, it can be a sunday....it can be 1 am it could be noon...
things like that are material and need to beb diclosed 

my beef with this all is that we should be at 70 cents wich is still a joke and were not...its gonna be tough to exercise these warrants at 1$but the company really could use the millions ...

id much rather her come out and say the deals are still in the works then to miss another vocalized deadline 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities